Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)
This grant funds research to develop and test precision drug-radiation combination therapies that exploit tumor-specific vulnerabilities, aiming to improve cancer treatment outcomes.
Funder: National Institutes of Health
Due Dates (Anticipated): November 2026 (Full application deadline, projected)
Funding Amounts: Exploratory/developmental projects: up to 2 years; research projects: 4–5 years; typical NIH award amounts based on project scope.
Summary: Supports research to develop precision radiation-synthetic combination strategies for new anticancer treatments, emphasizing context-dependent vulnerabilities.
Description
This forecasted Notice of Funding Opportunity (NOFO) from the National Cancer Institute (NCI) solicits research projects investigating actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The program aims to advance the development and adoption of radiation-synthetic combination strategies within the precision medicine toolkit, ultimately leading to new and more effective anticancer therapies.
The PAIRS initiative is unique in its focus on leveraging context-dependent effects of radiation therapy (RT) in combination with molecularly targeted agents. Projects should address innovative cancer therapy strategies that exploit RT-induced, context-specific tumor vulnerabilities, with an emphasis on precision, scientific rigor, and reproducibility. The program supports both exploratory/developmental projects (up to 2 years) and full research projects (4–5 years), streamlining previous funding mechanisms to accelerate progress in this research area.
